- 精神分裂症遗传风险与智商降低关...
- 非典型抗精神病药在青少年使用性...
- 产前服用抗癫痫药物丙戊酸钠增加...
- 老年患者使用抗精神病药要注意的
- 抗高血压药物硝普钠适用治疗精神...
- 吃出好心情
- 叶酸和精神疾病
- 5个简单问题预测精神病人的暴力...
- 门冬氨酸受体抗体在精神分裂症升...
- ω- 3脂肪酸和精神疾病
- 孕烯醇酮治疗精神分裂症的可能性
- 硝普钠迅速缓解精神分裂症的症状
- 痴呆的补充和替代疗法
- 产前服用抗癫痫药物丙戊酸钠增加...
- 噩梦的失眠可以关联抑郁症患者自...
- 睡眠质量预测临床前阿尔茨海默氏...
- 以色列科学家找出精神分裂症新的...
- (转)“灾难”让临床心理学家学...
- 治疗焦虑障碍的失眠
- 大脑中谷氨酸增高致精神分裂症
- 双相抑郁治疗和预防国际共识
- 多基因因素导致精神分裂症风险
- 精神分裂症的复发常有更多的尿路...
- 世界卫生组织对中国(H7N9)...
- 治疗强迫症的药物
- 非典型抑郁的诊断与治疗
- 对尚不能诊断为精神分裂症或精神...
- 治疗精神分裂症的问题(颜文伟)
- 快乐睡眠
- 光治疗改善老年抑郁症
- 催产素改善孤独症
- 经颅磁刺激治疗改善精神分裂症的...
- 轻度躯体异态可能反映出精神分裂...
- 精神分裂症与双相障碍的神经软体...
- 精神分裂症早期就要预防代谢疾病...
- 社交功能损害可能是精神分裂症早...
- 儿童双相障碍往往首发为抑郁症状
- 双相情感障碍和精神分裂症的社会...
- 精神分裂症患者并发症和死亡
- 怀孕期间使用SSRI死胎和新生...
- “抗氧化剂对有遗传脆弱性精神分...
- 血锂浓度正常的锂中毒 (喻东山...
- 补充叶酸和维生素B12可改善精...
- 赌博成瘾显示大脑白质异常类似物...
- 苯二氮卓类与致命的肺炎相关联
- FDA推荐低剂量唑吡坦用于失眠...
- 双相情感障碍存在代谢综合征危险...
- NMDA受体的抗抑郁作用
- 抗精神病药物的抗抑郁效果
- 焦虑症状的自我改善
- FDA requires sl...
- 未被发现的疾病增加精神分裂症的...
- 补充维生素C增加男性肾结石的风...
- FDA-approved me...
- 精神分裂症的不良饮食习惯易引起...
- 难治性精神分裂症与种族
- 难治性精神分裂症
- 精神病治疗的新方法
- 抗抑郁药物撤药症状
- 服用SSRIs增加脑出血的风险
- 童年急性应激增加精神障碍的风险
- 空气污染与儿童孤独症
- 酒精依赖的康复
- 处理酒精戒断症状
- The average lif...
- 证据显示突变基因引发精神分裂症
- 治疗强迫症
- 治疗强迫症进展
- 饮食与精神健康
- 膳食补充剂对精神分裂症的预防提...
- 服抗精神病药前需要向医生问些什...
- 治疗焦虑症的药物
- 治疗双相障碍的药物
- 治疗精神分裂症的药物
- 非典型抗精神病药对儿童情感障碍...
- 研究提示:青少年双相障碍患病率...
- 迅速短暂缓解抑郁的研究
- FDA对安眠药唑吡坦提出安全警...
- 联合使用抗抑郁药
- 精神疾病急性期治疗
- 精神疾病急性期治疗
- 使用抗精神病药基本原则
- 拮抗大脑中的谷氨酸盐可以防止自...
- 起效迅速 疗效持久的抗抑郁药问...
- 缺乏共情可能是精神障碍的特点
- 抑郁症患者中有不少是双相障碍
- 在中国文化程度低患精神分裂症的...
- 认识不够使治疗双相障碍治疗时间...
- 亚临床的双相抑郁
- 妊娠早期精神压力过大,增加孩子...
- 精神分裂症疗效不好时?
- FDA-批准的治疗酒精依赖药物
- “毒品”疫苗:药物依赖令人激动...
- 治疗迟发性运动障碍
- 美国食品和药物管理局批准另一个...
- 妊娠期是否服用抗抑郁药:一个艰...
- 睡眠不足会导致精神分裂症的症状...
- 精神障碍的危险因素与保护因素
- 缓解强迫症
- 大脑训练可以帮助提高老年人特定...
- 大脑训练可以帮助提高老年人特定...
- 科学解释:人们在得到鼓励后为何...
- 老年人服用苯二氮卓类药物可能增...
- 老年人服用苯二氮卓类药物可能增...
- 运动有益于精神分裂症患者的身体...
- 运动有益于精神分裂症患者的身体...
- 预防老年痴呆
- 预防老年痴呆
- 科学家荣获2012精神医学研究...
- 科学家荣获2012精神医学研究...
- 2011年美国农业部和美国卫生...
- 2011年美国农业部和美国卫生...
- 美国食品和药物管理局批准使用的...
- 美国食品和药物管理局批准使用的...
- 美国的各类精神障碍患者数量及患...
- 美国的各类精神障碍患者数量及患...
- 精神分裂症的早期征象
- 精神分裂症的早期征象
- 精神疾病与季节
- 精神疾病与季节
- 使人心情抑郁的十种药
- 使人心情抑郁的十种药
- 叶酸与抑郁症
- 叶酸与抑郁症
- 欧洲药品管理局建议降低西太普兰...
- 欧洲药品管理局建议降低西太普兰...
- 增加点维生素D可以减轻抑郁
- 增加点维生素D可以减轻抑郁
- 抗精神病药疗效降低的可能原因 ...
- 抗精神病药疗效降低的可能原因 ...
- 精神分裂症复发的早期表现
- 精神分裂症复发的早期表现
- 降低精神分裂症患病风险的策略
- 降低精神分裂症患病风险的策略
- 基因不是命运
- 基因不是命运
- 阿尔茨海默氏症治疗
- 阿尔茨海默氏症治疗
- 缓解精神压力小技巧
- 缓解精神压力小技巧
- 抗抑郁药临床治疗的选择[转载]
- 抗抑郁药临床治疗的选择[转载]
- 对精神疾病一些认识误区 (摘...
- 对精神疾病一些认识误区 (摘...
- 精神病药物疗效差的可能因素
- 精神病药物疗效差的可能因素
- 识别精神病的早期症状
- 识别精神病的早期症状
- 引起或诱发双相障碍的原因
- 引起或诱发双相障碍的原因
- the potential f...
- the potential f...
- 抑郁症与低胆固醇
- 抑郁症与低胆固醇
- 抑郁症复发的高危因素
- 抑郁症复发的高危因素
- 抗抑郁药物的停药一些问题
- 抗抑郁药物的停药一些问题
- 儿童孤独症的药物治疗
- 儿童孤独症的药物治疗
- 精神分裂症巩固期的合并用药
- 精神分裂症巩固期的合并用药
- Psychotropic Me...
- Psychotropic Me...
- ECT的副反应
- ECT的副反应
- 双相障碍药物长期治疗的一些问题
- 双相障碍药物长期治疗的一些问题
- 电休克治疗中 adequate...
- 电休克治疗中 adequate...
- 治疗迟发性运动障碍的药物
- 治疗迟发性运动障碍的药物
- 如何睡的更好
- 如何睡的更好
- 草药能否治疗抑郁症?
- 草药能否治疗抑郁症?
- 季节性情感障碍
- 季节性情感障碍
- 一小时内缓解抑郁症(Scien...
- 一小时内缓解抑郁症(Scien...
- 患双相情感障碍年轻女性在服用丙...
- 患双相情感障碍年轻女性在服用丙...
- 妊娠期电休克治疗的安全性
- 妊娠期电休克治疗的安全性
- 能对抗抑郁药快速反应的脑中的生物学标志发现
- 作者:朱健民|发布时间:2013-01-18|浏览量:1099次
Press Release • August 03, 2012
Brain Signal ID’s Responders to Fast-Acting Antidepressant
Biomarkers Help Pinpoint Mechanisms, Predict Outcomes?NIH Studies
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent’s underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.江西省精神病医院精神科朱健民
The signal is among the latest of several such markers, including factors detectable in blood, genetic markers, and a sleep-specific brain wave, recently uncovered by the NIH team and grantee collaborators. They illuminate the workings of the agent, called ketamine, and may hold promise for more personalized treatment.
“These clues help focus the search for the molecular targets of a future generation of medications that will lift depression within hours instead of weeks,” explained Carlos Zarate, M.D., of the NIH’s National Institute of Mental Health (NIMH). “The more precisely we understand how this mechanism works, the more narrowly treatment can be targeted to achieve rapid antidepressant effects and avoid undesirable side effects.”
Zarate, Brian Cornwell, Ph.D., and NIMH colleagues report on their brain imaging study online in the journal Biological Psychiatry.
Previous research had shown that ketamine can lift symptoms of depression within hours in many patients. But side effects hamper its use as a first-line medication. So researchers are studying its mechanism of action in hopes of developing a safer agent that works similarly.
Ketamine works through a different brain chemical system than conventional antidepressants. It initially blocks a protein on brain neurons, called the NMDA receptor, to which the chemical messenger glutamate binds. However, it is not known if the drug’s rapid antidepressant effects are a direct result of this blockage or of downstream effects triggered by the blockage, as suggested by animal studies.
To tease apart ketamine’s workings, the NIMH team imaged depressed patients’ brain electrical activity with magnetoencephalography (MEG). They monitored spontaneous activity while subjects were at rest, and activity evoked by gentle stimulation of a finger, before and 6.5 hours after an infusion of ketamine.
It was known that by blocking NMDA receptors, ketamine causes an increase in spontaneous electrical signals, or waves, in a particular frequency range in the brain’s cortex, or outer mantle. Hours after ketamine administration?in the timeframe in which ketamine relieves depression ? spontaneous electrical activity in people at rest was the same whether or not the drug lifted their depression.
Electrical activity evoked by stimulating a finger, however, was different in the two groups. MEG imaging made it possible to monitor excitability of the somatosensory cortex, the part of the cortex that registers sensory stimulation. Those who responded to ketamine showed an increased response to the finger stimulation, a greater excitability of the neurons in this part of the cortex.
Such a change in excitability is likely to result, not from the immediate effects of blocking the receptor, but from other processes downstream, in the cascade of effects set in motion by NMDA blockade, say the researchers. Evidence points to changes in another type of glutamate receptor, the AMPA receptor, raising questions about whether the blocking of NMDA receptors is even necessary for ketamine’s antidepressant effect. If NMDA blockade is just a trigger, then targeting AMPA receptors may prove a more direct way to effect a lifting of depression.
A separate study of ketamine biomarkers by the NIMH group adds to evidence that the drug may work, in part, bystrengthening neural connections. Thirty treatment resistant depressed patients who received ketamine showed increased sleep-specific slow brainwave activity (SWA) ? a marker of such strengthened synapses and of increased synchronization of networks in the cortex. They also had higher blood levels of a key neural growth chemical, brain-derived neurotrophic factor (BDNF), previously linked, in animal studies, to ketamine’s action. Intriguingly, the boosts in BDNF were proportional to those in SWA only among 13 participants whose depressions significantly lifted ? suggesting a potential marker of successful treatment.
“Linked SWA and BDNF may represent correlates of mood improvement following ketamine treatment,” said Zarate. “These may be part of the mechanism underlying the rapid antidepressant effects and prove useful in testing potential new therapies that target the glutamate system.”
The increases in SWA, detected via electroencephalography (EEG), were also reflected in increased slope and amplitude of individual brainwaves ? additional indicators of neural health and adaptability.
Prior to discovery of ketamine’s antidepressant effects, the only fast-acting antidepressant therapies were sleep deprivation and electroconvulsive therapy (ECT), both of which are also thought to work, at least in part, by stimulating BDNF.
There is also new evidence that people with one of two common versions of the gene that codes for BDNF respond better to ketamine ? and clues about why. The versions are created by a site in the human BDNF gene where thegenetic code differs slightly across individuals. Each person inherits two copies of the gene, one from each parent. So people can inherit one or two copies of each version.
In June, NIMH-funded researchers reported that ketamine’s ability to spur the growth of neural connections and trigger antidepressant-like behavioral responses was impaired in mice genetically engineered to express two copies of a risk version of the human BDNF gene that is carried by about 30 percent of the population. NIMH grantees George Aghajanian M.D., and Ronald Duman, Ph.D., of Yale University, New Haven, Conn., also discovered atrophy in extensions of neurons and dampened electrical activity in key cells at the front of the brain, with the risk version.
The mouse results suggested that the same site of variability in the BDNF gene might similarly influence patients’ responses to ketamine. In July, Zarate and NIMH colleagues reported that in 62 depressed patients, this variability in the BDNF gene accounted for 28 percent of difference in patients’ responsiveness to the medication. As expected, the antidepressant effect was strongest in patients with two copies of the other, protective version, which is carried by about 60 percent of the population.
These results strengthen the case for BDNF’s pivotal role in mediating antidepressant effects produced via the glutamate system. They also suggest that it might be possible to improve ketamine’s antidepressant effect in risk version carriers by first giving them treatments known to enhance BDNF, such as exercise, transcranial magnetic stimulation, ECT, or conventional antidepressants.
In another recent study by the NIMH team and NIH collaborators, by-products of the chemical breakdown of ketamine, detectable in blood, helped to sort out responders from non-responders, as well as diagnosis and symptoms. This first study of its kind pinpointed correlates of such downstream ketamine metabolites in 45 treatment resistant depressed unipolar and 22 depressed bipolar patients.
Blood levels of one metabolite were higher among bipolar non-responders, indicating that these patients might require a lower dose of the drug for optimal efficacy. Levels of three related metabolites were higher in bipolar patients, with only one, of a different type, elevated in patients with major depression. Higher levels of three metabolites of the former type were also associated with lower scores on measures of psychotic and other side effects, following ketamine treatment. The identification of these downstream metabolites opens the door to possibly developing them into newer treatments that are better tolerated than ketamine.
Ketamine also recently produced the fastest, strongest and longest-lasting anti-suicidal intervention ever demonstrated in a controlled trial, according to Zarate and colleagues. In a replication of an earlier study, the researchers confirmed that ketamine not only lifts depression, but also reduces suicidal thoughts in bipolar patients. The effects were detectable as soon as 40 minutes after a single infusion in 15 treatment resistant patients taking mood stabilizers, and remained significant for at least a few days. Three fourths of the patients responded to ketamine, with none responding to a placebo. The results add reduced suicidal thinking to the list of potential therapeutic benefits of targeting the brain’s glutamate system.
While the research on biological markers and mechanisms holds hope for development of more practical medications in the long term, questions remain about whether there might be a limited role for ketamine itself in the short term.
In a recent assessment of the state of the science, Zarate and American and European colleagues propose that intravenous ketamine may prove useful for acutely suicidal patients who receive treatment in hospital emergency rooms. It may also offer an alternative to ECT, long considered the treatment of last resort for treatment resistant depression, but fraught with concerns about cognitive side effects.
However, the researchers recommend against the use of ketamine outside of a hospital setting, citing potential cardiovascular and other risks. They note that anesthesiologists participate in the trials at NIMH and Mount Sinai School of Medicine, New York City which also require a 24-hour inpatient stay following drug infusion.
Among about 163 patients who have been studied to date, the drug has been well tolerated and seems a reasonable treatment option for most treatment resistant depressed patients, say the researchers. Studies are under way using nasally administered ketamine and other strategies to determine how the rapid antidepressant affect might best be sustained.
“We are investigating ketamine in multiple ways ? studying genes, gene expression, synapses, cells, circuits, and symptoms with neuroimaging, genetics, electrophysiological measures and other techniques,” explained Zarate. “These studies hold hope for predicting the likelihood of response and for gaining insights into mechanisms of action.”
<!--[if !vml]--><!--[endif]-->
Dr. Zarate views subject in MEG scanner from scanner control room.
<!--[if !vml]--><!--[endif]-->
Images show response to finger stroking pre- and post-ketamine obtained by MEG scanning.
References
Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression. Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CA Jr. Biol Psychiatry. 2012 Apr 20. [Epub ahead of print] PMID: 22521148
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. Int J Neuropsychopharmacol. 2012 Jun 7:1-11. [Epub ahead of print] PMID: 22676966
Relationship of Ketamine"s Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression.Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, Moaddel R, Wainer IW. Biol Psychiatry. 2012 Apr 18. [Epub ahead of print]
PMID: 22516044
Replication of ketamine"s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Biol Psychiatry. 2012 Jun 1;71(11):939-46. Epub 2012 Jan 31.PMID: 22297150
Ketamine for Depression: Where Do We Go from Here? Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Biol Psychiatry. 2012 Jun 15. [Epub ahead of print] PMID: 22705040
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr. Biol Psychiatry. 2012 Jul 5. [Epub ahead of print] No abstract available. PMID:22771240
Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. Biol Psychiatry. 2012 Jun 1;71(11):996-1005. Epub 2011 Oct 29. PMID:22036038
TA的其他文章: